Boston Scientific Corporation (BSX) : Affinity Investment Advisors scooped up 47,305 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 1,100,073 shares of Boston Scientific Corporation which is valued at $26,247,742.Boston Scientific Corporation makes up approximately 1.88% of Affinity Investment Advisors’s portfolio.
Other Hedge Funds, Including , Tributary Capital Management reduced its stake in BSX by selling 17,530 shares or 13.01% in the most recent quarter. The Hedge Fund company now holds 117,200 shares of BSX which is valued at $2,796,392. Boston Scientific Corporation makes up approx 0.39% of Tributary Capital Management’s portfolio.Welch Forbes reduced its stake in BSX by selling 1,000 shares or 0.25% in the most recent quarter. The Hedge Fund company now holds 394,450 shares of BSX which is valued at $9,403,688. Boston Scientific Corporation makes up approx 0.28% of Welch Forbes’s portfolio.Msi Financial Services Inc boosted its stake in BSX in the latest quarter, The investment management firm added 1,580 additional shares and now holds a total of 4,186 shares of Boston Scientific Corporation which is valued at $99,041.Ls Investment Advisors reduced its stake in BSX by selling 1,170 shares or 2.96% in the most recent quarter. The Hedge Fund company now holds 38,355 shares of BSX which is valued at $917,452. Boston Scientific Corporation makes up approx 0.06% of Ls Investment Advisors’s portfolio.
Boston Scientific Corporation opened for trading at $23.9 and hit $23.94 on the upside on Wednesday, eventually ending the session at $23.9, with a gain of 0.13% or 0.03 points. The heightened volatility saw the trading volume jump to 64,05,207 shares. Company has a market cap of $32,522 M.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.